Leap Retained Earnings from 2010 to 2024

LPTX Stock

USD 3.30 0.14 4.43%

Leap Therapeutics Retained Earnings yearly trend continues to be fairly stable with very little volatility. Retained Earnings are likely to outpace its year average in 2024. Retained Earnings is the cumulative amount of net income that Leap Therapeutics retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2013-03-31

Previous Quarter

-433.8 M

Current Value

-451.9 M

Quarterly Volatility

119.1 M

Yuan Drop

Covid

Check Leap Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Leap Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 336.9 K, Interest Expense of 4.8 K or Selling General Administrative of 8.7 M, as well as many indicators such as Price To Sales Ratio of 110, Dividend Yield of 0.0025 or PTB Ratio of 1.41. Leap financial statements analysis is a perfect complement when working with Leap Therapeutics Valuation or Volatility modules.

Check out the analysis of Leap Therapeutics Correlation against competitors.

For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.

Latest Leap Therapeutics' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Leap Therapeutics over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Leap Therapeutics' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Leap Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (399.58 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Leap Retained Earnings Regression Statistics

	Arithmetic Mean	(162,479,660)
	Coefficient Of Variation	(79.44)
	Mean Deviation	107,226,659
	Median	(130,397,000)
	Standard Deviation	129,072,705
	Sample Variance	16659.8T
	Range	375.2M
	R-Value	(0.97)
	Mean Square Error	1148.9T
	R-Squared	0.94
	Slope	(27,922,137)
	Total Sum of Squares	233236.7T

Leap Retained Earnings History

	2024	-379.6 M
	2023	-399.6 M
	2022	-318.2 M
	2021	-263.6 M
	2020	-223 M
	2019	-195.2 M
	2018	-153.5 M

Other Fundumenentals of Leap Therapeutics

Retained Earnings Total Equity

Leap Therapeutics Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Property Plant Equipment	Short Term Debt	Current Deferred Revenue	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.81	-0.92	-0.64	0.45	0.11	0.33	1.0	0.29	0.69	-0.05	-0.34	0.37	0.71	-0.4	0.95	0.94	0.78
Total Stockholder Equity	0.81		-0.89	-0.52	0.28	-0.37	0.17	0.82	0.77	0.8	0.14	-0.79	0.08	0.62	-0.37	0.72	0.69	0.57
Net Debt	-0.92	-0.89		0.72	-0.54	0.03	-0.4	-0.92	-0.48	-0.88	-0.07	0.55	-0.4	-0.82	0.53	-0.93	-0.9	-0.73
Retained Earnings	-0.64	-0.52	0.72		-0.94	-0.27	-0.6	-0.64	-0.14	-0.6	-0.46	0.26	-0.78	-0.97	0.68	-0.7	-0.6	-0.55
Accounts Payable	0.45	0.28	-0.54	-0.94		0.43	0.67	0.44	-0.05	0.5	0.5	-0.1	0.88	0.91	-0.68	0.56	0.45	0.46
Net Receivables	0.11	-0.37	0.03	-0.27	0.43		0.47	0.11	-0.72	-0.18	-0.14	0.64	0.55	0.2	-0.23	0.21	0.23	0.26
Total Liab	0.33	0.17	-0.4	-0.6	0.67	0.47		0.33	0.07	0.45	0.12	-0.22	0.8	0.65	-0.86	0.36	0.3	0.33
Total Current Assets	1.0	0.82	-0.92	-0.64	0.44	0.11	0.33		0.3	0.69	-0.06	-0.35	0.36	0.7	-0.4	0.95	0.95	0.77
Common Stock	0.29	0.77	-0.48	-0.14	-0.05	-0.72	0.07	0.3		0.59	0.23	-0.99	-0.21	0.25	-0.27	0.16	0.12	0.16
Net Tangible Assets	0.69	0.8	-0.88	-0.6	0.5	-0.18	0.45	0.69	0.59		0.19	-0.66	0.35	0.75	-0.54	0.74	0.69	0.59
Property Plant Equipment	-0.05	0.14	-0.07	-0.46	0.5	-0.14	0.12	-0.06	0.23	0.19		-0.26	0.17	0.38	-0.02	-0.05	-0.15	-0.01
Short Term Debt	-0.34	-0.79	0.55	0.26	-0.1	0.64	-0.22	-0.35	-0.99	-0.66	-0.26		0.04	-0.38	0.42	-0.22	-0.17	-0.22
Current Deferred Revenue	0.37	0.08	-0.4	-0.78	0.88	0.55	0.8	0.36	-0.21	0.35	0.17	0.04		0.78	-0.82	0.48	0.36	0.45
Capital Surpluse	0.71	0.62	-0.82	-0.97	0.91	0.2	0.65	0.7	0.25	0.75	0.38	-0.38	0.78		-0.74	0.78	0.68	0.64
Deferred Long Term Liab	-0.4	-0.37	0.53	0.68	-0.68	-0.23	-0.86	-0.4	-0.27	-0.54	-0.02	0.42	-0.82	-0.74		-0.42	-0.33	-0.39
Net Invested Capital	0.95	0.72	-0.93	-0.7	0.56	0.21	0.36	0.95	0.16	0.74	-0.05	-0.22	0.48	0.78	-0.42		0.98	0.81
Net Working Capital	0.94	0.69	-0.9	-0.6	0.45	0.23	0.3	0.95	0.12	0.69	-0.15	-0.17	0.36	0.68	-0.33	0.98		0.76
Capital Stock	0.78	0.57	-0.73	-0.55	0.46	0.26	0.33	0.77	0.16	0.59	-0.01	-0.22	0.45	0.64	-0.39	0.81	0.76

Click cells to compare fundamentals

About Leap Therapeutics Financial Statements

Leap Therapeutics investors use historical fundamental indicators, such as Leap Therapeutics' Retained Earnings, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Leap Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Retained Earnings	-399.6 M	-379.6 M
Retained Earnings Total Equity	-237.2 M	-249.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Leap Stock Analysis

When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC